CP101

Unassigned

New Medicines

Prevention of recurrent Clostridioides difficile infection

Information

New molecular entity
Finch Therapeutics
Finch Therapeutics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Cell-based therapy. Full-spectrum microbiota therapy sourced from rigorously screened human donors
C. difficile is the main pathogen of antibiotic-associated colitis and accounts for up to 25% of hospital-acquired antibiotic-associated diarrhoea. Rate of infection was estimated as 43.0 in 2010/11 [2].
Prevention of recurrent Clostridioides difficile infection
Oral